Background: Ustekinumab, a monoclonal antibody targeting interleukins-12 and -23 is used to treat adults with Crohn's disease [CD]. We determined the 30-day postoperative infectious complication rate among CD patients who received ustekinumab within the 12 weeks prior to an abdominal operation as compared with patients who received anti-tumor necrosis factor [TNF] agents. Methods: A retrospective chart review of adults with CD who underwent an abdominal operation between January 1, 2015 and May 1, 2017 was performed across six sites. Surgical site infection [SSI] was defined as superficial skin and soft tissue infection, intra-abdominal abscess, anastomotic leak, and mucocutaneous separation of the stoma. Results: Forty-four patients received ustekinumab and 169 patients received anti-TNF therapy within the 12 weeks prior to surgery. The two groups were similar, except anti-TNF patients were more likely to have received combination therapy with an immunomodulator [P = 0.006]. There were no significant differences in postoperative SSI [13% in ustekinumab versus 20% in anti TNFtreated patients, p = 0.61] or hospital readmission rates [18% versus 10%, respectively, p = 0.14], but ustekinumab-treated patients had a higher rate of return to the operating room [16% versus 5%; P = 0.01]. There were no significant predictors identified on multivariable analysis. Conclusions: Of the 44 patients with CD who received ustekinumab within the 12 weeks prior to a major abdominal operation, 13% experienced a 30-day postoperative SSI, not statistically different from the 20% found in the anti-TNF cohort. Ustekinumab treatment within 12 weeks of surgery does not appear to increase the risk of postoperative SSI above that of CD patients treated with anti-TNF medications.
Introduction
The advent of the biologic era for the treatment of moderate to severe Crohn's disease [CD] was marked by the Federal Drug Administration [FDA] and European Medicine Agency's [EMA] approval of infliximab, an anti-tumor necrosis-alpha [TNF] inhibitor, in 1998. Despite its known safety and efficacy, clinically significant rates of primary non-response [1] [2] [3] [4] [5] and secondary non-response 6, 7 to anti-TNF agents has driven research to develop biologic therapies with alternative mechanisms of action. The anti-integrin medications natalizumab and vedolizumab were approved in 2008 and 2014, respectively, and most recently, in 2016, the anti-interleukin medication, ustekinumab [Stelara™, Janssen Biotech, Inc., Horsham, PA], was approved for moderately to severely active CD. Up to 75% of patients with CD will undergo a major abdominal operation during their lifetime, 8 and of these, up to one-third receive biology therapy in the perioperative period. As such, the effect of biologic therapy on postoperative outcomes has become an important issue to determine and address. To date, anti-TNF agents are the most well-studied biologics with regard to postoperative infectious complications. Meta-analyses report conflicting results regarding the association between postoperative complications in CD and preoperative exposure to anti-TNF therapy, 9 but prospective studies show an increased risk of postoperative infectious complications. 10 Vedolizumab, a monoclonal antibody to α4β7 integrin, has been widely adopted for its gut selectivity and theoretically improved safety profile. Vedolizumab has been found to be an independent predictor of postoperative infectious complications in one surgical case series, 11 but this finding was not confirmed in a subsequent study. 12 Postoperative outcomes in the setting of preoperative use of ustekinumab remain unstudied to date, largely due to the limited numbers of patients exposed to ustekinumab at any single given institution, as it has only been recently approved by the FDA and EMA for the treatment for adult CD.
In the Phase 2 and 3 studies demonstrating the efficacy of ustekinumab for the induction and maintenance of remission in patients with moderate to severe CD, [13] [14] [15] there was no increase in adverse events with ustekinumab, underscoring the safety profile of ustekinumab. However, the safety profile among surgical patients with regard to postoperative complications remains unknown. The risks of surgical site infections [SSIs] and anastomotic leaks are important considerations with any new immunosuppressive used perioperatively, as SSIs can significantly increase patient morbidity and length of hospital stay. 16, 17 Therefore, as the use of ustekinumab is increasing among CD patients, it is important to understand its impact on postoperative outcomes. We sought to determine the rate of postoperative infectious complications among CD patients who received ustekinumab within 12 weeks of a major abdominal operation as compared with patients exposed to anti-TNF therapy within 12 weeks of a major abdominal operation across multiple international inflammatory bowel disease referral centers. 
Materials and Methods

Statistical analysis
The statistical analysis was done using JMP software. Continuous variables were expressed as medians [interquartile range, IQR]. Comparisons between categorical variables were analyzed using the Pearson's chi-squared test, and comparisons between continuous variables were assessed with the Wilcoxon rank-sum test. A p value of <0.05 was considered statistically significant. Univariate and multivariable logistic regression were used to determine predictors of SSI among all CD patients as well as within the ustekinumab study cohort. Variables with p values of <0.05 in the univariate analysis were used in the multivariable model.
Results
A total of 213 patients were included in the analysis: 44 patients who received ustekinumab and 169 who received anti TNF therapy within 12 weeks of an abdominal operation between January 1, 2015 and May 1, 2017 at all of the six sites combined. Within the ustekinumab group, 27 patients were female [61%], the median age was 35 years [IQR, 24- 
Discussion
Ustekinumab, a humanized monoclonal antibody to IL-12 and -23, has been shown in clinical trials to be more effective than placebo to induce clinical response and maintain clinical remission in patients with moderate to severe CD [both in patients who have failed conventional therapy and those who have failed anti-TNF therapy]. [13] [14] [15] While the risk of postoperative infectious complications in the setting of anti-TNF therapy and vedolizumab remains controversial, no study to date has yet analysed postoperative complications in the setting of ustekinumab. In this combined international inflammatory bowel disease referral center retrospective cohort, we found that 13% of CD patients who received ustekinumab within 12 weeks of a major abdominal operation had a 30-day postoperative SSI, equivalent to the 20% rate in patients exposed to anti-TNF therapy. On multivariable regression analysis, there were no independent predictors of 30-day postoperative SSI.
Immunosuppressive therapy, while important for healing of luminal inflammation in CD, often ultimately proves ineffective, culminating in a patient developing an intestinal complication IQR, interquartile range; SSI, surgical site infection. Univariate predictors with p value < 0.05 were used for multivariable model. that results in a major abdominal operation. Corticosteroids have been widely studied and consistently associated with an increased risk for 30-day postoperative infectious complications. 20 Immunomodulators, on the other hand, have not been strongly associated with postoperative infectious complications. 18 However, similar to corticosteroids, anti-TNF agents may be associated with an increased rate of postoperative infectious complications, especially in patients with CD. 19, 21 The largest study to date suggests vedolizumab is an independent risk factor for postoperative infectious complications, 11 but this remains inadequately studied and controversial. 12 In our study of ustekinumab, we demonstrated that the rate of all postoperative SSI-related complications [superficial SSI, mucocutaneous separation, deep space SSI, and anastomotic leak] were not significantly increased as compared with the anti-TNF control cohort, and, on multivariable analysis exposure to ustekinumab was not an independent risk factor for postoperative SSI. These results suggest ustekinumab is as safe in the perioperative period as anti-TNF medications.
In contrast to some previous studies, we did not find any predictors of post-operative SSI in the CD cohorts. Previous research has found increased BMI, 22 smoking, 23 DM, 24 decreased albumin, 22 preoperative corticosteroid use, and immunomodulator therapy all to be associated with increased rates of SSI. Thus, we included all these factors in our data collection. On univariate analysis, only preoperative albumin level and preoperative corticosteroid use were associated with increased rates of SSI, but these did not remain significant on multivariable analysis. It may be that our sample size was too small to show statistical differences.
There are several limitations to this study. First, this is a combined-center retrospective review performed at six large inflammatory bowel disease referral centers. Therefore, there may be great variability in the way these patients are managed intraoperatively and postoperatively. In fact, the difference in returns to the operating room may have been due to different practices across referral centers, as one site accounted for all returns to the operating room in ustekinumab-treated patients, and 9 of the total 14 returns to the operating room. Interestingly, however, there were no significant differences found in the postoperative outcomes across the sites. Second, since ustekinumab was only recently approved by the FDA in 2016, our study only captures a year and half of data prior to September 2016, including patients who received the drug as part of a clinical trial. Therefore, we only had 44 ustekinuamb-treated patients and 169 anti-TNF-treated patients. Since our difference in SSI rate between the two groups was 7%, we would need a sample size of 440 patients for each group to detect a significant difference with p = 0.05 and a power of 80%. With our current sample size, the difference is only powered to 18%. Thus, in order to better understand the safety of ustekinumab in the perioperative period and its association with 30-day postoperative infectious complications, it will be important to collect data from larger numbers of patients and study postoperative complications in a prospective manner. Third, we did not stratify patients based on the numbers of days between discontinuing biologic therapy and performing an operation. Given the half-life of ustekinumab is 21 days, while infliximab, adalimumab and certolizumab have half-lives of 10, 14 and 11 days, respectively, the results may be affected by the wash-out period prior to surgery.
In conclusion, ustekinumab was not associated with an increased rate of postoperative infectious complications in adult CD patients. Our study's 30-day SSI rate was 13%, a rate not significantly higher than that of patients receiving anti-TNF perioperatively. Given the small number of patients included in this series, further study will be needed to confirm our findings in a larger cohort of patients.
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